S'abonner

Epicutaneous immunotherapy induces gastrointestinal LAP+ regulatory T cells and prevents food-induced anaphylaxis - 18/04/17

Doi : 10.1016/j.jaci.2016.03.057 
Leticia Tordesillas, PhD a, b, Lucie Mondoulet, PhD c, Ana Belen Blazquez, PhD a, b, Pierre-Henri Benhamou, PhD c, Hugh A. Sampson, MD a, b, d, M. Cecilia Berin, PhD a, b, d, e,
a Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 
b Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 
c DBV Technologies, Bagneux, France 
d Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY 
e Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 

Corresponding author: M. Cecilia Berin, PhD, Pediatric Allergy & Immunology, Box 1198, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029.Pediatric Allergy & ImmunologyBox 1198, Icahn School of Medicine at Mount SinaiOne Gustave L. Levy PlaceNew YorkNY10029

Abstract

Background

The attempt to induce oral tolerance as a treatment for food allergy has been hampered by a lack of sustained clinical protection. Immunotherapy by nonoral routes, such as the skin, may be more effective for the development of maintained tolerance to food allergens.

Objective

We sought to determine the efficacy and mechanism of tolerance induced by epicutaneous immunotherapy (EPIT) in a model of food-induced anaphylaxis.

Methods

C3H/HeJ mice were sensitized to ovalbumin (OVA) orally or through the skin and treated with EPIT using OVA-Viaskin patches or oral immunotherapy using OVA. Mice were orally challenged with OVA to induce anaphylaxis. Antigen-specific regulatory T (Treg)-cell induction was assessed by flow cytometry using a transgenic T-cell transfer model.

Results

By using an adjuvant-free model of food allergy generated by epicutaneous sensitization and reactions triggered by oral allergen challenge, we found that EPIT induced sustained protection against anaphylaxis. We show that the gastrointestinal tract is deficient in de novo generation of Treg cells in allergic mice. This defect was tissue-specific, and epicutaneous application of antigen generated a population of gastrointestinal-homing LAP+Foxp3 Treg cells. The mechanism of protection was found to be a novel pathway of direct TGF-β–dependent Treg-cell suppression of mast cell activation, in the absence of modulation of T- or B-cell responses.

Conclusions

Our data highlight the immune communication between skin and gastrointestinal tract, and identifies novel mechanisms by which epicutaneous tolerance can suppress food-induced anaphylaxis.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Epicutaneous immunotherapy, oral immunotherapy, food allergy, regulatory T cells, mast cells

Abbreviations used : CT, EPIT, LAP, MLN, OIT, Treg


Plan


 Graphical abstract printed with permission from Mount Sinai Health System. Figure created by Jill K. Gregory, CMI.
 This study was supported by the National Institutes of Health (grant no. AI093577 to M.C.B.), David H. and Julia Koch Research Program in Food Allergy Therapeutics (to H.A.S.), and Robin Chemers Neustein Fellowship (to L.T.).
 Disclosure of potential conflict of interest: L. Tordesillas received travel support from DBV Technologies (the developer and owner of the Viaskin patch) to present this work in part at the European Academy of Allergy and Clinical Immunology. L. Mondoulet is an employee of DBV Technologies and receives research support, support for travel, and payment for writing or reviewing the manuscript from DBV Technologies. P.-H. Benhamou is CEO of DBV Technologies, serves on the board, and receives research support, travel support, and stock options. H. A. Sampson receives research support from the National Institute of Allergy and Infectious Diseases (NIAID); serves as a consultant for Allertein Therapeutics, LLC, Genentech, Sanofi, Stallergens, and Merck; is an employee of DBV Technologies as Chief Scientific Officer; and holds stock options in Allertein Therapeutics and DBV Therapeutics. M. C. Berin receives research support from the NIAID and receives travel support from DBV Technologies. A. B. Blazquez declares that she has no relevant conflicts of interest.


© 2016  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 139 - N° 1

P. 189 - janvier 2017 Retour au numéro
Article précédent Article précédent
  • Trends, characteristics, and incidence of anaphylaxis in 2001-2010: A population-based study
  • Sangil Lee, Erik P. Hess, Christine Lohse, Waqas Gilani, Alanna M. Chamberlain, Ronna L. Campbell
| Article suivant Article suivant
  • DNA demethylation of inflammasome-associated genes is enhanced in patients with cryopyrin-associated periodic syndromes
  • Roser Vento-Tormo, Damiana Álvarez-Errico, Antonio Garcia-Gomez, José Hernández-Rodríguez, Segundo Buján, Maria Basagaña, Maria Méndez, Jordi Yagüe, Manel Juan, Juan I. Aróstegui, Esteban Ballestar

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.